Glucagon like peptide-1 receptor expression in the human thyroid gland

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 1, 2012, Pages 121-131

  Gier, Belinda ^a   Butler, Peter C ^a   Lai, Chi K ^a   Kirakossian, David ^a   DeNicola, Matthew M ^a   Yeh, Michael W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ADULT; AGED; ARTICLE; CELL HYPERPLASIA; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; THYROID CELL; THYROID GLAND; THYROID MEDULLARY CARCINOMA;

ADULT; AGED; ANIMALS; CERCOPITHECUS AETHIOPS; CHO CELLS; COS CELLS; CRICETINAE; CRICETULUS; FEMALE; GENE EXPRESSION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERPLASIA; MALE; MIDDLE AGED; RECEPTORS, GLUCAGON; THYROID GLAND; THYROID NEOPLASMS; TISSUE DISTRIBUTION; VALIDATION STUDIES AS TOPIC; YOUNG ADULT;

RODENTIA;

EID: 84855489636     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2407     Document Type: Article

References (33)

1. Aaboe K, Krarup T, Madsbad S, Holst JJ 2008 GLP-1: physiological effects and potential therapeutic applications. Diabetes Obes Metab 10:994-1003
2. Peters A 2010 Incretin-based therapies: review of current clinical trial data. Am J Med 123:S28-S37
3. 2009 Victoza (R)(liraglutide injection):humanrelevance ofrodent thyroid C-cell tumors. http://www.fda.gov/downloads/AdvisoryCommittees/ Committees%20MeetingMaterials/Drugs/Endocrinologicand MetabolicDrugsAdvisoryCommittee/UCM151129.pdf. Accessed October 5, 2010
4. Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, Gotfredsen C, Egerod FL, Hegelund AC, Jacobsen H, Jacobsen SD, Moses AC, Mølck AM, Nielsen HS, Nowak J, Solberg H, Thi TD, Zdravkovic M 2010 Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151:1473-1486
5. Rosai J, Carcangiu ML, DeLellis RA 1992 Tumors of the thyroid gland. In: Rosai J, ed. Atlas of tumor pathology. Bethesda, MD: Armed Forces Institute of Pathology
6. Körner M, Stöckli M, Waser B, Reubi JC 2007 GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 48:736-743
7. Guyétant S, Rousselet MC, Durigon M, Chappard D, Franc B, Guerin O, Saint-André JP 1997 Sex-related C cell hyperplasia in the normal human thyroid: a quantitative autopsy study. J Clin Endocrinol Metab 82:42-47
8. Perry A, Molberg K, Albores-Saavedra J 1996 Physiologic versus neoplastic C-cell hyperplasia of the thyroid: separation of distinct histologic and biologic entities. Cancer 77:750-756
9. Negrete OA, Levroney EL, Aguilar HC, Bertolotti-Ciarlet A, Nazarian R, Tajyar S, Lee B 2005 EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature 436:401-405
10. Unson CG 2008 Expression of glucagon receptors in tetracycline-inducible HEK293S GnT1-stable cell lines: an approach toward purification of receptor protein for structural studies. Biopolymers 90: 287-296
11. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD, Ellis KS, Woods SC, Seeley RJ, Herman JP, D'Alessio DA 2007 Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148:4965-4973
12. Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB 2000 Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucosestimulated insulin secretion. Diabetes 49:424-430
13. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC 2011 Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141:150-156
14. Bondeson L, Ljungberg O 1984 Occult papillary thyroid carcinoma in the young and the aged. Cancer 53:1790-1792
15. Tschen SI, Dhawan S, Gurlo T, Bhushan A 2009 Age-dependent decline in β-cell proliferation restricts the capacity of β-cell regeneration in mice. Diabetes 58:1312-1320
16. Liu Z, Habener JF 2008 Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic β cell proliferation. J Biol Chem 283:8723-8735
17. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ 2009 Cancer statistics, 2009. CA Cancer J Clin 59:225-249
18. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells Jr SA 2009 Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565-612
19. LiVolsi VA 1997 C cell hyperplasia/neoplasia. J Clin Endocrinol Metab 82:39-41
20. Livolsi VA, Feind CR 1979 Incidental medullary thyroid carcinoma in sporadic hyperparathyroidism. An expansion of the concept of C-cell hyperplasia. Am J Clin Pathol 71:595-599
21. Verga U, Ferrero S, Vicentini L, Brambilla T, Cirello V, Muzza M, Beck-Peccoz P, Fugazzola L 2007 Histopathological and molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia? Endocr Relat Cancer 14:393-403
22. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L 2009 Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallelgroup, multinational, open-label trial (LEAD-6). Lancet 374:39-47
23. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B 2009 Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373:473-481
24. Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S 2009 Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 26:268-278
25. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR 2009 Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32:84-90
26. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R 2009 Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52:2046-2055
27. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L 2009 Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32:1224-1230
28. Hegedüs L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH 2011 GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 96:853-860
29. Hirsch PF, Baruch H 2003 Is calcitonin an important physiological substance? Endocrine 21:201-208
30. Wang W, Lewin E, Olgaard K 2002 Role of calcitonin in the rapid minute-to-minute regulation of plasma Ca2+ homeostasis in the rat. Eur J Clin Invest 32:674-681
31. Albores-Saavedra JA, Krueger JE 2001 C-cell hyperplasia and medullary thyroid microcarcinoma. Endocr Pathol 12:365-377
32. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167
33. Butler PC, Dry S, Elashoff R 2010 GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care 33:453-455